In this secondary analysis of the ECOG-ACRIN E2906 study, researchers assessed vulnerabilities of AML patients aged 60 years or older and their affect on survival outcomes.

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

Patients with acute myeloid leukemia (AML) in remission for 3 years have survival rates similar to the general population, but long-term needs remain poorly understood. A retrospective analysis showed ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...